New targeted pill could boost lung cancer surgery success

NCT ID NCT07622706

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to remove their cancer. The main goal is to see how many patients have a major response in their tumor tissue after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Firmonertinib (also known as AST-2818), an oral targeted therapy
What this could lead to: If successful, this could show that taking firmonertinib before surgery helps shrink tumors and may improve long-term outcomes for people with EGFR-mutated lung cancer.
What could go wrong: This is a small, early-phase trial with no comparison group, so results may not be definitive. Side effects from the drug or surgery are possible, and the approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR POSITIVE NON-SMALL CELL LUNG CANCER NEOADJUVANT THERAPY NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.